

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:

NEW ASSIGNMENT

NATURE OF CONVEYANCE:

ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Questcor Pharmaceuticals, Inc.	10/13/2005

RECEIVING PARTY DATA

Name:	QOL Medical LLC
Street Address:	516-D River Highway
Internal Address:	158
City:	Mooresville
State/Country:	NORTH CAROLINA
Postal Code:	28117-6830

PROPERTY NUMBERS Total: 1

Property Type	Number
Patent Number:	4724231

CORRESPONDENCE DATA

Fax Number: (214)981-3400

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 214-981-3300

Email: jchester@sidley.com

Correspondent Name: Julia M. Chester, Esq.

Address Line 1: 717 N. Harwood

Address Line 2: Suite 3400

Address Line 4: Dallas, TEXAS 75201

ATTORNEY DOCKET NUMBER:

27472-50640

NAME OF SUBMITTER:

Julia M. Chester

Total Attachments: 7

source=QUESTCOR#page1.tif

source=QUESTCOR#page2.tif

PATENT

REEL: 016686 FRAME: 0432

500057400

CH \$40.00 4724231

source=QUESTCOR#page3.tif
source=QUESTCOR#page4.tif
source=QUESTCOR#page5.tif
source=QUESTCOR#page6.tif
source=QUESTCOR#page7.tif

PATENT ASSIGNMENT

WHEREAS, Questcor Pharmaceuticals, Inc., a California Corporation, (hereinafter referred to as "Assignor"), owns certain pharmaceutical product lines, for which Assignor it has previously received Letters Patent of the United States, as more fully described in Schedule A, which is attached hereto and made a part hereof;

WHEREAS, Assignor is the owner of all rights, title, and interest in and to the patents described in Schedule A;

WHEREAS, the patents set forth on Schedule A hereto have either expired or lapsed; and

WHEREAS, QOL Medical LLC, a limited liability company (hereinafter referred to as "Assignee"), is desirous of obtaining any rights, title and interests in, to and under the patents described in Schedule A that may still remain vested in Assignor.

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR agrees as follows:

1. Assignor hereby sells, assigns, transfers and sets over, unto the Assignee, its successors, legal representatives and assigns, all rights and interests it may have in, to and under the patents listed on Schedule A and the inventions and improvements described therein, and all divisionals, renewals and continuations thereof, and all Letters Patents of the United States that may be granted thereon and all reissues, patents of addition, reexaminations, substitutions, revivals, and extensions thereof and all applications for Letters Patents that may hereafter be filed for the inventions and improvements in any country or countries foreign to the United States, including those claiming priority to the patents described in Schedule A and all Letters Patents that may be granted for the inventions or improvements in any country or countries foreign to the United States and all extensions, renewals, revivals, and reissues thereof, and any and all rights to sue and recover for past infringement or misappropriation of any one of the rights embodied in any of the foregoing for Assignee's own use and enjoyment and for the use and enjoyment of its successors, assigns or other legal representatives, and to recover damages and payments for past, present or future infringements or misappropriations thereof.

2. Assignor hereby authorizes and requests the Commissioner of Patents of the United States, and any official of any country or countries foreign to the United States whose duty it is to issue patents on applications as aforesaid, to issue all Letters Patents for the inventions and improvements to the Assignee, its successors, legal representatives and assigns, in accordance with the terms of this instrument.

3. Assignor hereby represents and warrants that Assignor has not executed, and will not execute any agreement in conflict herewith.

4. Assignor hereby further covenants and agrees that Assignor will communicate to the Assignee, its successors, legal representatives and assigns, any facts known to Assignor respecting the patents described in Schedule A, and will testify in any legal proceeding, sign all lawful papers, execute all divisional, continuing and reissue applications, make all rightful oaths and generally do everything reasonably possible to aid the Assignee, its successors, legal representatives and assigns, to obtain and enforce proper patent protection for the inventions and improvements in all countries.

5. ASSIGNOR EXPRESSLY DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, WITH REGARD TO THE VALIDITY AND ENFORCEABILITY OF THE PATENTS LISTED ON SCHEDULE A HERETO.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, ASSIGNOR has caused this instrument to be executed by its duly authorized officer on this 13th day of October, 2005.

QUESTCOR PHARMACEUTICALS, INC.

By: James J. Fares
Its: President & CEO

STATE OF CALIFORNIA


)
) ss
)

COUNTY OF ORANGE

On October 13, 2005 before me, L. St. Charles, Notary Public, personally appeared James L. Fares, personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose names is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity, and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

WITNESS my hand and official seal

L. St. Charles
SIGNATURE OF NOTARY PUBLIC



SCHEDULE A

SEE ATTACHED SCHEDULE

SCHEDULE A

1. U.S. Patent No. 4,724,231 "Nasal Compositions Containing Vitamin B 12" issued February 9, 1988. Expired April 16, 2005
2. E.U. Patent No. EP021 691 7B 1 "Nasal Compositions Containing Vitamin B 12."
3. E.U. Patent No. EP021 8679B 1 "Aerosol Compositions for Nasal Delivery of Vitamin B12."

<u>Title</u>	<u>Appl'n No.</u>	<u>Patent No.</u>	<u>Country</u>	<u>Filing Date</u>	<u>Issue Date</u>
Aerosol Compositions for Nasal Delivery of Vitamin B12 (20833-000700CA) 719-21CANADA	506,798	1,317,881	Canada	04/16/86	05/18/93
Aerosol Compositions for Nasal Delivery of Vitamin B12 (20833-000700EP) 719-21PCT/EPO	86-902640.1	0218679	Europe	04/02/86	12/11/91
Aerosol Compositions for Nasal Delivery of Vitamin B12 (20833-000700BE)	86-902640.1	0218679	Belgium	04/02/86	12/11/91
Aerosol Compositions for Nasal Delivery of Vitamin B12 (20833-000700FR)	86-902640.1	0218679	France	04/02/86	12/11/91
Aerosol Compositions for Nasal Delivery of Vitamin B12 (20833-000700GB)	86-902640.1	0218679	Great Britain	04/02/86	12/11/91
Aerosol Compositions for Nasal Delivery of Vitamin B12 (20833-000700DB)	86-902640.1	P3682862.9	Denmark	04/02/86	12/11/91
Aerosol Compositions for Nasal Delivery of Vitamin B12 (20833-000700IT)	g6-902640.1	0218679	Italy	04/02/86	12/11/91
Aerosol Compositions for Nasal Delivery of Vitamin B12 (20833-000700LU)	86-902640.1	0218679	Luxembourg	04/02/86	12/11/91
Aerosol Compositions for Nasal Delivery of Vitamin B12 (20833-000700NL)	86-902640.1	0218679	Netherlands	04/02/86	12/11/91
Aerosol Compositions for Nasal Delivery of Vitamin B12 (20833-000700SB)	86-902640.1	0218679	Sweden	04/02/86	12/11/91
Aerosol Compositions for Nasal Delivery of Vitamin B12 (20833-000700CH)	86-902640.1	0218679	Switzerland	04/02/86	12/11/91
Nasal Compositions Containing Vitamin B12 (20833-000610US) 719-16CIP	06/848,690	4,724,231	US	04/08/86	02/09/88

DOC/SOC/1125329v1/10025-0004

Nasal Compositions Containing Vitamin B12 (20833-00061OPC) 719-16CIPCT	PCT/1JS86/007			04/15/86	
Nasal Compositions Containing Vitamin B12 (20833-00061OAU)	57757/86	584703	Australia	04/15/86	10/20/89
Nasal Compositions Containing Vitamin B12 (20833-00061OCA)	506,799	1,300,014	Canada	04/26/86	05/05/92
Nasal Compositions Containing Vitamin B12 (20833-00061OEP) 719-16CJP/PCT/EPO	86902732.6	0216917	Europe	04/15/86	07/04/90
Nasal Compositions Containing Vitamin B12 (20833-00061OBE)	86902732.6	0216917	Belgium	04/15/86	07/04/90
Nasal Compositions Containing Vitamin B12 EP86902732.6	603 8/86		Denmark	04/15/86	
(20833-00061ODK)					
Nasal Compositions Containing Vitamin B12 (20833-00061OFR)	86902732.6	0216917	France	04/15/86	07/04/90
Nasal Compositions Containing Vitamin B12 (20833-00061OGB)	86902732.6	0216917	Great Britain	04/15/86	07/04/90
Nasal Compositions Containing Vitamin B12 (20833-00061ODB) (German P/N	86902732.6	0216917	Germany	04/15/86	07/04/90
Nasal Compositions Containing Vitamin B12 (20833-00061OIE)	974/86	58533	Ireland	04/15/86	09/27/93
Nasal Compositions Containing Vitamin B12 (20833-00061OIT)	86902732.6	0216917	Italy	04/15/86	07/04/90
Nasal Compositions Containing Vitamin B12 (20833-00061OLU)	86902732.6	0216917	Luxembourg	04/15/86	07/04/90
Nasal Compositions Containing Vitamin B12 (20833-00061ONL)	86902732.6	0216917	Netherlands	04/15/86	07/04/90
Nasal Compositions Containing Vitamin B12 (20833-00061OES) ICI-004	553,999	553,999	Spain	04/15/86	04/20/87
Nasal Compositions Containing Vitamin B12 (20833-00061OSB)	86902732.6	0216917	Sweden	04/15/86	07/04/90
Nasal Compositions Containing Vitamin B12 (20833-00061OCM)	86902732.6	0216917	Switzerland	04/15/86	07/04/90
Nasal Compositions Containing Vitamin B12	2345/86	196124	Hungary	04/15/86	06/16/88

DOCSOC/1125329v1/10025-0004

(20833-00061OHU)	502336/86	1945666	Japan	04/15/86	06/23/95
Nasal Compositions Containing Vitamin B12 (20833-00061OW)					
Nasal Compositions Containing Vitamin B12 (20833-00061ON0)	865010	174.182	Norway	04/15/86	03/30/94
Nasal Compositions Containing Vitamin B12 (20833-00061OZA)	86/2845	86/2845	South Africa	04/16/86	10/29/86
Nasal Compositions Containing Vitamin B12 (20833-00061OTW)	75102030	NI-029728	Taiwan	05/06/86	12/10/88

DOC SOC/1125329v1/10025-0004